Wednesday, April 13, 2016 8:46:00 PM
From the SEC filing
https://www.sec.gov/Archives/edgar/data/1072379/000114420416075320/0001144204-16-075320-index.htm
Northwest Biotherapeutics, Inc. (the “Company”) is filing this prospectus supplement and accompanying prospectus to register for potential resale 15,177,739 previously-issued shares (the “Shares”) of our common stock, par value $0.001 per share (the “Common Stock”) sold to Woodford Investment Management LLP (“Woodford”, or the “Selling Shareholder”) in three separate transactions. On November 17, 2014, we entered into a Stock Purchase Agreement with Woodford to sell 4,317,789 shares of Common Stock at the price of $5.79 per share. On April 2, 2015, we entered into a Stock Purchase Agreement with Woodford to sell 5,405,405 shares of Common Stock in two, separate installments, each at the price of $7.40 per share. On October 21, 2015, we entered into a Stock Purchase Agreement with Woodford to sell 5,454,545 shares of Common Stock at the price of $5.50 per share. Pursuant to each of the Stock Purchase Agreements, we agreed to register the Shares on behalf of Woodford.
“You have not lived today until you have done something for someone who cannot pay you back!” - John Bunyon
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
